CERTARA

Simcyp

Academic Licenses

Simcyp grants academic licenses for the Simcyp Simulator to centers of excellence in research related to drug development. Academic license agreements differ from Consortium member contracts to reflect the not-for-profit nature of the research. This makes them more accessible to scientists on non-commercial budgets

Simcyp is committed to high quality research and development. We feel it is essential that the world's leading academic institutes for pharmaceutical research have access to the same advanced tools that are used by the industry. In addition, due to the growing trend towards "virtual" evaluation of drugs, it is imperative that the next generation of industry researchers is appropriately trained in the use of modern modeling and simulation techniques and our young scientists appreciate the true value of using *in vitro* data in the prediction of in vivo outcomes.

Research and teaching uses

The Simcyp Simulator is a valuable tool in undergraduate and postgraduate education and has been used to support the teaching of topics such as advanced pharmacokinetics, drug metabolism and disposition, dosage form design and clinical study design and interpretation.

The Simulator has wide applications in academic research and current ongoing projects include the analysis of exposure-dose-toxicity relationships, the assessment of inter-individual variability on drug bioavailability, prediction of drug-drug interactions and covariate analyses in pediatric patients.

As part of the licensing agreement, users must attend the Simcyp workshops on model-based drug development prior to using the Simulator in teaching and research activities.

Over 90 institutions hold academic licenses including: University at Buffalo, University of Florida, University of Gothenburg, Leiden University, University of Manchester, University of North Carolina-Chapel Hill, Showa Pharmaceutical University and University of Washington.

How relevant is the Simcyp Simulator? The Simcyp Simulator has been developed in consultation with the world's leading pharmaceutical and biotechnology companies which make up the Simcyp Consortium.* The Simulator is updated regularly to satisfy the requirements of the industry and regulatory scientists who use the platform.

*Simcyp Consortium members include: Actelion, AstraZeneca, Daiichi-Sankyo, Eli Lilly, Eisai, Johnson & Johnson PRD, Lundbeck, Novartis Pharma, Otsuka, Pfizer, Sanofi, Servier, Takeda, and UCB Pharma.

> "Projects comprising *in silico* components are very appealing to students and, therefore, having access to the Simcyp Simulator helps attract honors and higher-degree candidates... the interactive nature of the Simcyp Simulator facilitates a teaching environment that enhances student learning, helping to maintain excellence in teaching via cutting-edge technology."
>
> – Academic Simcyp project coordinator

Simcyp academic awards

Since 2010 and the rise in the use of the Simcyp Population-based Simulator in academic and not-for-profit teaching and research projects, we have presented the 'Annual Simcyp Academic Awards.' The awards aim to recognize innovative teaching methods and cutting-edge published research in the fields of *in vitro–in vivo* extrapolation (IVIVE), absorption, distribution, metabolism, and excretion (ADME), physiologically-based pharmacokinetics (PBPK), pharmaceutics, biologics, safety pharmacology, and modeling and simulation.

All academic and not-for-profit research institutions currently holding Simcyp licenses are eligible to apply.

Most Effective Teaching Application: This award will be granted to an academic group demonstrating the 'Best Use of the Simcyp Simulator in Teaching' in the field of IVIVE, ADME, PBPK, pharmaceutics, biologics, safety pharmacology, and modeling and simulation.

The winner will receive a monetary contribution towards the cost of travel to and registration at a scientific meeting of their choice within a year of receipt of the award. Alternatively, the contribution can be allocated to assist with the cost of travel and accommodation to take a three week sabbatical within Simcyp to work with the Science Team on projects of mutual interest.

Most Informative Scientific Report: This award will be granted to the lead author of a scientific publication judged to be 'The Most Informative Application of the Simcyp Simulator' in the field of IVIVE, ADME, PBPK, pharmaceutics, biologics, safety pharmacology, and modeling and simulation.

The winning group will receive a monetary contribution towards either computer hardware (PC, laptop, projector, etc.) or software. Alternatively, the contribution can be allocated to assist with the cost of travel and accommodation for a member of the team to take a three week sabbatical within Simcyp or to attend Simcyp Workshops.

Simcyp virtual seminar

Each September, the Simcyp Consortium meeting provides an excellent forum for the exchange of scientific ideas relating to IVIVE and the Simcyp Simulator. To allow for increased interaction among our associate members who hold academic and not-for-profit Simulator licenses, we have now built on this success by hosting a 'virtual' seminar which focuses on the Applications of Automated Population-based IVIVE and PBPK.

The virtual seminar is held annually and conducted via webinar so that all users and interested parties from member institutions can log on from anywhere in the world. It provides a forum for presentations and discussions on the latest teaching and research in the field and is hugely beneficial, both for Simcyp and the academic community. The seminar also presents an opportunity to showcase the Simcyp academic awards.

About Certara

Certara is a leading provider of decision support technology and consulting services for optimizing drug development and improving health outcomes. Certara's solutions, which span the drug development and patient care lifecycle, help increase the probability of regulatory and commercial success by using the most scientifically advanced modeling and simulation technologies and regulatory strategies. Its clients include hundreds of global biopharmaceutical companies, leading academic institutions and key regulatory agencies.

For more information visit www.certara.com or email sales@certara.com.

BR Nov 2016 v1 111716